DCC-2618, a novel pan-KIT and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST).
DCC-2618, a novel pan-KIT and PDGFRα kinase switch control inhibitor, shows encouraging signal in a patient with glioblastoma (GBM).
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Pharmacokinetic (PK), Safety, and Tolerability Profile of DCC-2618 in a Phase 1 Clinical Trial Supports 150mg QD Selected for a Pivotal Phase 3 Study in Gastrointestinal Stromal Tumor (GIST).
Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618.
Mutation Profile of Drug Resistant GIST Patients Enrolled in the Phase 1 Study of DCC-2618
Initial Results of Phase 1 Study of DCC-2618, a Broad-Spectrum KIT and PDGFR⍺ Inhibitor, in Patients (PTS) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimens.
DCC-2618, a broad-spectrum inhibitor of KIT and PDGFRA mutants,synergizes with inhibitors of the MAPK pathway.
Ripretinib (DCC-2618) Pharmacokinetics (PK) in a Phase 1 Study in Patients with Gastrointestinal Stromal Tumors (GIST) and other Advanced Malignancies: A Retrospective Evaluation of the PK Effects of Proton Pump Inhibitors (PPIs).
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
